Evolocumab is an injectable antibody that powerfully lowers bad cholesterol by removing a natural brake on the liver's ability to clear it. It lowers the chance of heart attacks and strokes, especially in higher-risk people, with a notably clean safety profile. Whether it lengthens overall lifespan, and its long-term effects and high cost, remain open. (Full Review)

Protocol

Dosing

140 mg every 2 weeks or 420 mg monthly

Subcutaneous injection; choice driven by preference and adherence.

Regimen

Add-on to maximally tolerated statin and often ezetimibe

Or primary agent in statin-intolerant or familial hypercholesterolemia patients.

Timing

Any time of day; consistency of interval matters

No time-of-day dependence given the long half-life.

Time to effect

LDL reduction

1–2 weeks

Substantial LDL reduction evident within the first 1–2 weeks.

Near-maximal LDL effect

4–8 weeks

Near-maximal LDL effect reached by 4–8 weeks.

Cardiovascular benefit

Months to years

Cardiovascular-risk benefits accrue over months to years of sustained use.

Benefits

High: Substantial LDL cholesterol reduction; reduced risk of heart attack, stroke, and coronary revascularization; reduction of apolipoprotein B and non-HDL cholesterol

Medium: Slowing or regression of atherosclerotic plaque; lipoprotein(a) lowering

Low: Benefit in statin-intolerant individuals

Speculative: All-cause mortality and longevity extension

Contraindications

Serious hypersensitivity to evolocumab (severe rash or angioedema)

Pregnancy and breastfeeding

Key Interactions

Other PCSK9-directed therapy (inclisiran)

Risk & Side Effects

High: Injection-site reactions

Medium: Flu-like and upper-respiratory symptoms; neutralizing antibody formation

Low: Theoretical concerns from very low LDL cholesterol; new-onset diabetes

Speculative: Rare atrial fibrillation and isolated case reports

Monitoring

Marker	Target	Why
LDL cholesterol	<70 mg/dL (often <55 mg/dL in high-risk)	Primary target of therapy
Apolipoprotein B (apoB)	<60–80 mg/dL (lower for high-risk longevity goals)	Most accurate count of atherogenic particles
Lipoprotein(a) [Lp(a)]	<75 nmol/L (≈ <30 mg/dL)	Independent, genetic cardiovascular risk factor evolocumab modestly lowers
Non-HDL cholesterol	<100 mg/dL (lower for high-risk)	Captures all atherogenic cholesterol beyond LDL
ALT / AST (liver enzymes)	Within or below conventional reference range	Baseline organ-function check and ongoing reassurance
Fasting glucose / HbA1c	Fasting glucose <90 mg/dL; HbA1c <5.4%	Cardiometabolic context; reassurance no diabetes signal

Cadence: Recheck at ~4–8 weeks after initiation, then every 3–6 months during the first year, and every 6–12 months thereafter once stable. Lp(a) once.

Qualitative Assessment

Tolerability of injections (local reactions, ease of self-administration)
General energy and well-being
Absence of new muscle symptoms (relevant when transitioning from statins)
Adherence and confidence with the dosing routine

Evolocumab for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment